Disease · MONDO_0005595
laryngeal squamous cell carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. laryngeal squamous cell carcinoma. Diseases, record MONDO_0005595. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005595
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
LSCC, epidermoid carcinoma of larynx, epidermoid carcinoma of the larynx, laryngeal epidermoid carcinoma, laryngeal throat squamous cell cancer, larynx epidermoid carcinoma, larynx squamous cell carcinoma, squamous cell carcinoma of larynx, squamous cell carcinoma of the larynx
- Open Targets
Drugs26
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 19 | 19 | 19 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 5 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AVELUMAB | CHEMBL3833373 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PANITUMUMAB | CHEMBL1201827 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TISLELIZUMAB | CHEMBL4297840 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRETINOIN | CHEMBL38 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 26
See all 26 drugsTargets95
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 95
See all 95 targetsTrials32
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00265941 | Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer | Phase 3 | 940 | 2017-12-21 | Head and Neck Cancer | CETUXIMAB, CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02952586 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) | Phase 3 | 697 | 2021-02-24 | Squamous Cell Carcinoma of the Head and Neck | AVELUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02347332 | Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer | Phase 3 | 459 | 2019-02-04 | Recurrent or Metastatic Head and Neck Carcinoma | METHOTREXATE, VINFLUNINE | Its record names the disease | ClinicalTrials.gov |
| NCT03067610 | Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer | Phase 2 | 72 | 2022-03-17 | Head and Neck Cancer, Carcinoma, Squamous Cell, Neoplasms, Oral, Neoplasms, Pharyngeal | CARBOPLATIN, CETUXIMAB, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT01633541 | Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer | Phase 2 | 55 | 2023-07-20 | Laryngeal Cancer | CARBOPLATIN, CISPLATIN, DOCETAXEL, ISOSORBIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02949700 | Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | Phase 1/2 | 26 | 2022-07-21 | Head and Neck Squamous Cell Carcinoma | METFORMIN | Its record names the disease | ClinicalTrials.gov |
| NCT00882583 | A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC | Phase 1 | 22 | 2017-02-23 | Head and Neck Cancer | CETUXIMAB, CISPLATIN, DASATINIB ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT02759575 | A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma | Phase 1/2 | 9 | 2021-03-12 | Head and Neck Cancer | CISPLATIN, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06706401 | Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma | Phase 3 | 460 | Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor | CETUXIMAB, CISPLATIN, TRETINOIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03843671 | Hyperbaric Radiation Sensitization of Head and Neck Cancers | Phase 2 | 400 | Squamous Cell Carcinoma of the Head and Neck | OXYGEN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 32
See all 32 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| RT + Cisplatin vs RT + Cisplatin + Cetuximab: serious adverse events | 208 of 447 | 237 of 444 | 891 | NCT00265941 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: deaths from any cause | 86 of 348 | 62 of 344 | 692 | NCT02952586 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: serious adverse events | 184 of 348 | 177 of 344 | 692 | NCT02952586 | Trial comparisons |
| Vinflunine Plus Methotrexate vs Methotrexate: deaths from any cause | 185 of 225 | 194 of 227 | 452 | NCT02347332 | Trial comparisons |
| Vinflunine Plus Methotrexate vs Methotrexate: serious adverse events | 106 of 225 | 81 of 227 | 452 | NCT02347332 | Trial comparisons |
| Platinum/Docetaxal + AT-101 vs Active Comparator Arm: deaths from any cause | 1 of 36 | 1 of 18 | 54 | NCT01633541 | Trial comparisons |
| Platinum/Docetaxal + AT-101 vs Active Comparator Arm: serious adverse events | 14 of 36 | 5 of 18 | 54 | NCT01633541 | Trial comparisons |
| Platinum/Docetaxal + AT-101 vs Active Comparator Arm: Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment | 27 of 34 | 12 of 18 | 52 | NCT01633541 | Trial comparisons |
| Cohort A vs Cohort B: deaths from any cause | 1 of 7 | 1 of 12 | 19 | NCT00882583 | Trial comparisons |
| Cohort A vs Cohort B: serious adverse events | 1 of 7 | 5 of 12 | 19 | NCT00882583 | Trial comparisons |
Papers from its trials24
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005595
GET https://conductscience.org/api/diseases/v1/MONDO_0005595/drugs?page=2